Latest & greatest articles for prostate cancer

The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on prostate cancer or other clinical topics then use Trip today.

This page lists the very latest high quality evidence on prostate cancer and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.

What is Trip?

Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.

Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.

As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.

For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via jon.brassey@tripdatabase.com

Top results for prostate cancer

121. A Web-Based Intervention to Reduce Distress After Prostate Cancer Treatment: Development and Feasibility of the Getting Down to Coping Program in Two Different Clinical Settings Full Text available with Trip Pro

A Web-Based Intervention to Reduce Distress After Prostate Cancer Treatment: Development and Feasibility of the Getting Down to Coping Program in Two Different Clinical Settings Distress after prostate cancer treatment is a substantial burden for up to one-third of men diagnosed. Physical and emotional symptoms and health service use can intensify, yet men are reticent to accept support. To provide accessible support that can be cost effectively integrated into care pathways, we developed (...) a unique, Web-based, self-guided, cognitive-behavior program incorporating filmed and interactive peer support.To assess feasibility of the intervention among men experiencing distress after prostate cancer treatment. Demand, acceptability, change in distress and self-efficacy, and challenges for implementation in clinical practice were measured.A pre-post, within-participant comparison, mixed-methods research design was followed. Phase I and II were conducted in primary care psychological service

2018 JMIR cancer

122. Hedgehog in prostate cancer explained Full Text available with Trip Pro

Hedgehog in prostate cancer explained 29854872 2018 11 14 2331-4737 5 3-4 2018 Mar Oncoscience Oncoscience Hedgehog in prostate cancer explained. 67-68 10.18632/oncoscience.405 Buttyan Ralph R The Vancouver Prostate Centre, Vancouver BC V6H 3Z6 Canada. Li Na N The Vancouver Prostate Centre, Vancouver BC V6H 3Z6 Canada. Massah Shabnam S The Vancouver Prostate Centre, Vancouver BC V6H 3Z6 Canada. eng Editorial 2018 04 29 United States Oncoscience 101636666 2331-4737 Androgen Receptors Gli (...) Hedgehog Steroid Receptors prostate cancer CONFLICTS OF INTEREST The authors declare no potential conflicts of interest. 2018 04 12 2018 04 21 2018 6 2 6 0 2018 6 2 6 0 2018 6 2 6 1 epublish 29854872 10.18632/oncoscience.405 405 PMC5978441 Eur J Cancer. 2006 Mar;42(4):437-45 16406505 Prostate. 2014 Oct;74(14 ):1400-10 25132524 Cancer Chemother Pharmacol. 2016 Dec;78(6):1297-1304 27826729 Cell Mol Life Sci. 2000 Nov;57(12 ):1720-31 11130178 Oncogene. 2018 Apr;37(17 ):2313-2325 29429990 Horm Cancer. 2014

2018 Oncoscience

123. Germline genetic testing in prostate cancer – further enrichment in variant histologies? Full Text available with Trip Pro

Germline genetic testing in prostate cancer – further enrichment in variant histologies? 29854870 2018 11 14 2331-4737 5 3-4 2018 Mar Oncoscience Oncoscience Germline genetic testing in prostate cancer - further enrichment in variant histologies? 62-64 10.18632/oncoscience.403 Markowski Mark C MC Departments of Oncology and Urology, Johns Hopkins Sidney Kimmel Cancer Center, Baltimore, MD 21287, USA. Antonarakis Emmanuel S ES Departments of Oncology and Urology, Johns Hopkins Sidney Kimmel (...) Cancer Center, Baltimore, MD 21287, USA. eng Editorial 2018 04 29 United States Oncoscience 101636666 2331-4737 CONFLICTS OF INTEREST The authors declare no potential conflicts of interest. 2018 03 29 2018 03 29 2018 6 2 6 0 2018 6 2 6 0 2018 6 2 6 1 epublish 29854870 10.18632/oncoscience.403 403 PMC5978447 N Engl J Med. 2016 Aug 4;375(5):443-53 27433846 Cell. 2015 May 21;161(5):1215-1228 26000489 Eur Urol. 2017 Jul;72 (1):34-42 28259476 Cell. 2015 Nov 5;163(4):1011-25 26544944 Eur Urol. 2018 May;73

2018 Oncoscience

124. Androgen Deprivation Therapy Is Associated With Prolongation of QTc Interval in Men With Prostate Cancer Full Text available with Trip Pro

Androgen Deprivation Therapy Is Associated With Prolongation of QTc Interval in Men With Prostate Cancer Androgen deprivation therapy (ADT) for prostate cancer (PCa) is associated with increased cardiovascular mortality and sudden cardiac death, with some events occurring early after initiation of ADT. Testosterone levels are inversely associated with corrected QT (QTc) interval duration; therefore, prolongation of QTc duration could be responsible for some of these events during ADT.To

2018 Journal of the Endocrine Society

125. Salvage Pelvic Lymph Node Dissection After Fluciclovine Positron Emission Tomography/Computed Tomography Detected Prostate Cancer Recurrence Full Text available with Trip Pro

Salvage Pelvic Lymph Node Dissection After Fluciclovine Positron Emission Tomography/Computed Tomography Detected Prostate Cancer Recurrence Background: Multiple new systemic agents have been targeted to metastatic prostate cancer, with decreased progression of disease but no cure. Surgical management of metastatic disease has been gaining interest, primarily in the setting of high-risk prostatectomies. However, metastasis-directed surgical intervention has been employed in rare scenarios (...) , especially in oligometastatic disease. We report here on a salvage robot-assisted pelvic lymph node dissection for a solitary metastatic site. Case Presentation: A 63-year-old Hispanic man who was initially treated with prostatectomy for intermediate risk cancer developed rapid biochemical recurrence. After salvage radiation, fluciclovine positron emission tomography (PET)/computed tomography (CT) scan showed a solitary pelvic lymph node metastasis. A robot-assisted laparoscopic pelvic lymph node

2018 Journal of endourology case reports

126. Patient-reported outcomes following abiraterone acetate plus prednisone added to androgen deprivation therapy in patients with newly diagnosed metastatic castration-naive prostate cancer (LATITUDE): an international, randomised phase 3 trial (Abstract)

Patient-reported outcomes following abiraterone acetate plus prednisone added to androgen deprivation therapy in patients with newly diagnosed metastatic castration-naive prostate cancer (LATITUDE): an international, randomised phase 3 trial In the LATITUDE trial, addition of abiraterone acetate plus prednisone to androgen deprivation therapy (ADT) improved overall survival compared with placebos plus ADT in patients with newly diagnosed, high-risk, metastatic castration-naive prostate cancer (...) , by use of the Brief Pain Inventory-Short Form (BPI-SF), Brief Fatigue Inventory (BFI), Functional Assessment of Cancer Therapy Prostate scale (FACT-P), and the EuroQol (EQ-5D-5L) questionnaires. PRO analyses were an exploratory endpoint. Analyses were by intention-to-treat. Results from the first pre-planned interim analysis (Oct 31, 2016), are presented here. This ongoing study is registered with Clinicaltrials.gov, number NCT01715285.Between Feb 12, 2013, and Dec 11, 2014, 1199 patients were

2018 EvidenceUpdates

127. Apalutamide (Erleada) - prostate cancer

Apalutamide (Erleada) - prostate cancer Drug Approval Package: ERLEADA (apalutamide) U.S. Department of Health and Human Services Search FDA Submit search Drug Approval Package: ERLEADA (apalutamide) This review package includes Clinical Study Reports as part of a pilot project. The Clinical Study Report section provides information for pivotal clinical trials, not for all studies in the application. Company: Janssen Biotech Application Number: 210951 Orig 1 Approval Date: 02/14/2018 Persons

2018 FDA - Drug Approval Package

128. Chemohormonal Therapy in Metastatic Hormone-Sensitive Prostate Cancer: Long-Term Survival Analysis of the Randomized Phase III E3805 CHAARTED Trial Full Text available with Trip Pro

follow-up and focus on tumor volume. Patients and Methods In this phase III study, 790 patients with metastatic hormone-sensitive prostate cancer were equally randomly assigned to receive either ADT in combination with docetaxel 75 mg/m2 for up to six cycles or ADT alone. The primary end point of the study was overall survival (OS). Additional analyses of the prospectively defined low- and high-volume disease subgroups were performed. High-volume disease was defined as presence of visceral metastases (...) Chemohormonal Therapy in Metastatic Hormone-Sensitive Prostate Cancer: Long-Term Survival Analysis of the Randomized Phase III E3805 CHAARTED Trial Purpose Docetaxel added to androgen-deprivation therapy (ADT) significantly increases the longevity of some patients with metastatic hormone-sensitive prostate cancer. Herein, we present the outcomes of the CHAARTED (Chemohormonal Therapy Versus Androgen Ablation Randomized Trial for Extensive Disease in Prostate Cancer) trial with more mature

2018 EvidenceUpdates

129. MRI-Targeted or Standard Biopsy for Prostate-Cancer Diagnosis. Full Text available with Trip Pro

MRI-Targeted or Standard Biopsy for Prostate-Cancer Diagnosis. Multiparametric magnetic resonance imaging (MRI), with or without targeted biopsy, is an alternative to standard transrectal ultrasonography-guided biopsy for prostate-cancer detection in men with a raised prostate-specific antigen level who have not undergone biopsy. However, comparative evidence is limited.In a multicenter, randomized, noninferiority trial, we assigned men with a clinical suspicion of prostate cancer who had (...) not undergone biopsy previously to undergo MRI, with or without targeted biopsy, or standard transrectal ultrasonography-guided biopsy. Men in the MRI-targeted biopsy group underwent a targeted biopsy (without standard biopsy cores) if the MRI was suggestive of prostate cancer; men whose MRI results were not suggestive of prostate cancer were not offered biopsy. Standard biopsy was a 10-to-12-core, transrectal ultrasonography-guided biopsy. The primary outcome was the proportion of men who received

2018 NEJM Controlled trial quality: predicted high

130. Effect of a Low-Intensity PSA-Based Screening Intervention on Prostate Cancer Mortality: The CAP Randomized Clinical Trial. Full Text available with Trip Pro

with prostate cancer was higher in the intervention group (n = 8054; 4.3%) than in the control group (n = 7853; 3.6%) (RR, 1.19 [95% CI, 1.14 to 1.25]; P < .001). More prostate cancer tumors with a Gleason grade of 6 or lower were identified in the intervention group (n = 3263/189 386 [1.7%]) than in the control group (n = 2440/219 439 [1.1%]) (difference per 1000 men, 6.11 [95% CI, 5.38 to 6.84]; P < .001). In the analysis of all-cause mortality, there were 25 459 deaths in the intervention group vs 28 306 (...) Effect of a Low-Intensity PSA-Based Screening Intervention on Prostate Cancer Mortality: The CAP Randomized Clinical Trial. Prostate cancer screening remains controversial because potential mortality or quality-of-life benefits may be outweighed by harms from overdetection and overtreatment.To evaluate the effect of a single prostate-specific antigen (PSA) screening intervention and standardized diagnostic pathway on prostate cancer-specific mortality.The Cluster Randomized Trial of PSA Testing

2018 JAMA Controlled trial quality: predicted high

131. Radical Prostatectomy, External Beam Radiotherapy, or External Beam Radiotherapy With Brachytherapy Boost and Disease Progression and Mortality in Patients With Gleason Score 9-10 Prostate Cancer. Full Text available with Trip Pro

Radical Prostatectomy, External Beam Radiotherapy, or External Beam Radiotherapy With Brachytherapy Boost and Disease Progression and Mortality in Patients With Gleason Score 9-10 Prostate Cancer. The optimal treatment for Gleason score 9-10 prostate cancer is unknown.To compare clinical outcomes of patients with Gleason score 9-10 prostate cancer after definitive treatment.Retrospective cohort study in 12 tertiary centers (11 in the United States, 1 in Norway), with 1809 patients treated (...) between 2000 and 2013.Radical prostatectomy (RP), external beam radiotherapy (EBRT) with androgen deprivation therapy, or EBRT plus brachytherapy boost (EBRT+BT) with androgen deprivation therapy.The primary outcome was prostate cancer-specific mortality; distant metastasis-free survival and overall survival were secondary outcomes.Of 1809 men, 639 underwent RP, 734 EBRT, and 436 EBRT+BT. Median ages were 61, 67.7, and 67.5 years; median follow-up was 4.2, 5.1, and 6.3 years, respectively. By 10 years

2018 JAMA

132. Prostate cancer medicine Xofigo must not be used with Zytiga and prednisone/prednisolone

Prostate cancer medicine Xofigo must not be used with Zytiga and prednisone/prednisolone Prostate cancer medicine Xofigo must not be used with Zytiga and prednisone/prednisolone | European Medicines Agency Search Search Menu Prostate cancer medicine Xofigo must not be used with Zytiga and prednisone/prednisolone Press release 09/03/2018 Ongoing clinical study shows an increased risk of death and fractures with the combination The European Medicines Agency (EMA) has recommended contraindicating (...) the use of the prostate cancer medicine Xofigo (radium-223 dichloride) with Zytiga (abiraterone acetate) and prednisone/prednisolone, due to an increased risk of death and fractures with this combination. EMA's ( ) has reviewed the preliminary data from an ongoing clinical study in metastatic prostate cancer patients. In this study 34.7% of patients treated with Xofigo, Zytiga and prednisone/prednisolone have died so far, compared with 28.2% of patients given placebo, Zytiga and prednisone

2018 European Medicines Agency - EPARs

133. Initial toxicity, quality-of-life outcomes, and dosimetric impact in a randomized phase 3 trial of hypofractionated versus standard fractionated proton therapy for low-risk prostate cancer Full Text available with Trip Pro

Initial toxicity, quality-of-life outcomes, and dosimetric impact in a randomized phase 3 trial of hypofractionated versus standard fractionated proton therapy for low-risk prostate cancer Randomized evidence for extreme hypofractionation in prostate cancer is lacking. We aimed to identify differences in toxicity and quality-of-life outcomes between standard fractionation and extreme hypofractionated radiation in a phase 3 randomized trial.We analyzed the results of the first 75 patients in our (...) phase 3 trial, comparing 38 Gy relative biologic effectiveness (RBE) in 5 fractions (n = 46) versus 79.2 Gy RBE in 44 fractions (n = 29). Patients received proton radiation using fiducials and daily image guidance. We evaluated American Urological Association Symptom Index (AUASI), adverse events (AEs), and Expanded Prostate Index Composite (EPIC) domains. The primary endpoint of this interim analysis was the cumulative incidence of grade 2 (G2) or higher AEs. The randomized patient allocation

2018 Advances in radiation oncology Controlled trial quality: predicted high

134. Apalutamide Treatment and Metastasis-free Survival in Prostate Cancer. Full Text available with Trip Pro

Apalutamide Treatment and Metastasis-free Survival in Prostate Cancer. Apalutamide, a competitive inhibitor of the androgen receptor, is under development for the treatment of prostate cancer. We evaluated the efficacy of apalutamide in men with nonmetastatic castration-resistant prostate cancer who were at high risk for the development of metastasis.We conducted a double-blind, placebo-controlled, phase 3 trial involving men with nonmetastatic castration-resistant prostate cancer (...) of the trial regimen was 10.6% in the apalutamide group and 7.0% in the placebo group. The following adverse events occurred at a higher rate with apalutamide than with placebo: rash (23.8% vs. 5.5%), hypothyroidism (8.1% vs. 2.0%), and fracture (11.7% vs. 6.5%).Among men with nonmetastatic castration-resistant prostate cancer, metastasis-free survival and time to symptomatic progression were significantly longer with apalutamide than with placebo. (Funded by Janssen Research and Development; SPARTAN

2018 NEJM Controlled trial quality: predicted high

135. Localised prostate cancer - immediate treatment, or not?

Localised prostate cancer - immediate treatment, or not? Prescrire IN ENGLISH - Spotlight ''Localised prostate cancer - immediate treatment, or not?'', 1 February 2018 {1} {1} {1} | | > > > Localised prostate cancer - immediate treatment, or not? Spotlight Every month, the subjects in Prescrire’s Spotlight. 100 most recent :  |   |   |   |   |   |   |   |   |  Spotlight In the February issue of Prescrire International (...) : Localised prostate cancer - immediate treatment, or not? FREE DOWNLOAD In patients with localised prostate cancer, the principal therapeutic options are: monitoring without initial treatment, prostatectomy and radiotherapy. Results of a comparative randomised trial have provided some useful data for providing information to patients. Full text available for free download. Summary In a randomised trial including 1643 patients with localised prostate cancer, all detected by PSA screening, the mortality

2018 Prescrire

136. Risk of prostate cancer across different racial/ethnic groups in men with diabetes: a retrospective cohort study (Abstract)

Risk of prostate cancer across different racial/ethnic groups in men with diabetes: a retrospective cohort study To examine the associations between prostate cancer, diabetes and race/ethnicity.Using administrative data from British Columbia, Canada for the period 1994 to 2012, we identified men aged ≥50 years with and without diabetes. Validated surname algorithms identified men as Chinese, Indian or of other race/ethnicity. Multivariable Cox regression was used to estimate adjusted risks (...) of prostate cancer according to diabetes status and race/ethnicity.Our cohort of 160 566 men had a mean (sd) age of 64.7 (9.4) years and a median of 9 years' follow-up. The incidence rates of prostate cancer among those with and without diabetes were 177.4 (171.7-183.4) and 216.0 (209.7-222.5) per 1000 person-years, respectively. The incidence among Chinese men was 120.9 (109.2-133.1), among Indian men it was 144.1 (122.8-169.0) and in men of other ethnicity it was 204.8 (200.2-209.5). Diabetes

2018 EvidenceUpdates

137. Ablative techniques for the treatment of localised prostate cancer

cryotherapy, irreversible electroporation, MRI-guided laser ablation and radiofrequency ablation, may address this clinical need, as there is some evidence that they have less toxicity than conventional therapies. However, the efficacy of these therapies is unclear, as several studies have shown high rates of persistent malignancy in the prostate glands so treated. Given that ablative techniques are offered as curative therapies for early prostate cancer and they are competing with well-established (...) with Prostate Cancer'. J Urol. 4. Ting, F., Tran, M. et al (2016). 'Focal irreversible electroporation for prostate cancer: Functional outcomes and short-term oncological control'. Prostate Cancer and Prostatic Diseases, 19 (1), 46-52. 5. Valerio, M., Stricker, P. D. et al (2014). 'Initial assessment of safety and clinical feasibility of irreversible electroporation in the focal treatment of prostate cancer'. Prostate Cancer and Prostatic Diseases, 17 (4), 343-7. 6. Eggener, S. E., Yousuf, A. et al (2016

2018 COAG Health Council - Horizon Scanning Technology Briefs

138. Development and Validation of a Novel Integrated Clinical-Genomic Risk Group Classification for Localized Prostate Cancer Full Text available with Trip Pro

Development and Validation of a Novel Integrated Clinical-Genomic Risk Group Classification for Localized Prostate Cancer Purpose It is clinically challenging to integrate genomic-classifier results that report a numeric risk of recurrence into treatment recommendations for localized prostate cancer, which are founded in the framework of risk groups. We aimed to develop a novel clinical-genomic risk grouping system that can readily be incorporated into treatment guidelines for localized (...) prostate cancer. Materials and Methods Two multicenter cohorts (n = 991) were used for training and validation of the clinical-genomic risk groups, and two additional cohorts (n = 5,937) were used for reclassification analyses. Competing risks analysis was used to estimate the risk of distant metastasis. Time-dependent c-indices were constructed to compare clinicopathologic risk models with the clinical-genomic risk groups. Results With a median follow-up of 8 years for patients in the training cohort

2018 EvidenceUpdates

139. Comparative effectiveness review of cryoablation for salvage treatment of recurrent prostate cancer following radiotherapy

recurrence of prostate cancer; however, questions remain about the long-term efficacy for local and distant tumor control and survival. Relevant Questions: Does salvage cryoablation provide effective local tumor control and acceptable rates of remission and long-term disease-free survival in patients with recurrent prostate cancer following failure of RT? Does salvage cryoablation provide acceptable outcomes with regard to urinary function, prostate symptoms, and sexual function? How does salvage (...) cryoablation compare with other salvage treatment options for recurrent prostate cancer, including radical prostatectomy (RP)? Is salvage cryoablation safe, and what are the related complications? Have definitive patient selection criteria been established for salvage cryoablation treatment for recurrent prostate cancer? Final publication URL The report may be purchased from: Indexing Status Subject indexing assigned by CRD MeSH Chronic Disease; Cryosurgery; Humans; Male; Neoplasm Recurrence, Local

2018 Health Technology Assessment (HTA) Database.

140. Comparative effectiveness review of cryoablation for primary treatment of localized prostate cancer

control to improve survival. Controversy: Locally ablative therapies such as cryoablation may have less morbidity compared with other primary treatment options for localized prostate cancer; however, questions remain about the long-term efficacy for local and distant tumor control and survival. Relevant Questions: Does cryoablation provide effective local tumor control and acceptable rates of remission and long-term disease-free survival in patients with primary localized prostate cancer? Does (...) inserted cryoprobes to freeze and, thereby, destroy cancerous prostate tissue. This outpatient procedure has been evaluated for patients with prostate cancer who prefer a less invasive option than prostatectomy or who are not appropriate surgical candidates. Rationale: The goals of the minimally invasive cryoablation treatment for localized prostate cancer are to use focused cryoablation energy to ablate the entire prostate gland or the cancer-containing part of the gland and achieve complete tumor

2018 Health Technology Assessment (HTA) Database.